ArticleCurrent infectious disease reports2012
Vaccination against rheumatic heart disease: a review of current research strategies and challenges.
Article in Current infectious disease reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease.Nature reviews. Cardiology · 2013Guideline
- Tonsils at Telethon: developing a standardised collection of tonsil photographs for group A streptococcal (GAS) research.Frontiers in pediatrics · 2024Article
- A pilot study to develop assessment tools for Group A Streptococcus surveillance studies.PeerJ · 2023Article
- Health system and patient-level factors serving as facilitators and barriers to rheumatic heart disease care in Sudan.Global health research and policy · 2021Article
- Molecular Epidemiology, Ecology, and Evolution of Group A Streptococci.Microbiology spectrum · 2018Review
- Towards developing a vaccine for rheumatic heart disease.Global cardiology science & practice · 2017Review
- Article
- The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design.Cell host & microbe · 2014Article
- StreptInCor: a model of anti-Streptococcus pyogenes vaccine reviewed.Auto- immunity highlights · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are major health problems in many developing countries and Indigenous populations of developed countries. ARF and RHD are sequelae resulting from an infection of Streptococcus pyogenes. Despite advances in health care practices and technology, these diseases still pose major challenges in the communities where Streptococcus pyogenes is often endemic. Here we review and discuss the dynamic epidemiology of streptococcal infection and its associated diseases (ARF and RHD), with a focus on disease burden in temperate versus tropical regions, the tissue tropism of the organism and the efforts towards vaccine development in relation to the available animal models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.